HALO

Halozyme Therapeutics Inc

Add to Watchlist

Advanced Chart

58.240

-0.53(-0.902%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

58.930

Open

58.750

VWAP

58.37

Vol

1.10M

Mkt Cap

7.18B

Low

58.020

Amount

63.96M

EV/EBITDA(TTM)

11.69

Total Shares

123.22M

7.94B

EV/OCF(TTM)

15.75

P/S(TTM)

6.92

Halozyme Therapeutics, Inc. is a biopharmaceutical company advancing solutions to improve patient experiences and outcomes for emerging and established therapies. The Company's commercially-validated solution, ENHANZE drug delivery technology with the proprietary enzyme rHuPH20, is used to facilitate the subcutaneous delivery of injected drugs and fluids, with a focus on improving the patient experience with rapid subcutaneous delivery and reduced treatment burden. The Company licenses its technology to biopharmaceutical companies to collaboratively develop products that combine ENHANZE with its partners’ proprietary compounds. It also develops, manufactures and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technologies. The Company has two commercial proprietary products, Hylenex and XYOSTED, partnered commercial products and ongoing product development programs with Teva Pharmaceuticals and Idorsia Pharmaceuticals.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2025Q3

362.53M

+21.65%

1.665

+32.18%

330.87M

+14.06%

1.441

+13.48%

Estimates Revision

The market is revising Upward the revenue expectations for Halozyme Therapeutics, Inc. (HALO) for FY2025, with the revenue forecasts being adjusted by 4.19% over the past three months. During the same period, the stock price has changed by -3.85%.

Revenue Estimates for FY2025

Revise Upward

+4.19%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+6.54%

In Past 3 Month

Stock Price

Go Down

-3.85%

In Past 3 Month

9 Analyst Rating

12.76% Upside

Wall Street analysts forecast HALO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HALO is 65.67 USD with a low forecast of 47.00 USD and a high forecast of 79.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

5 Buy

3 Hold

1 Sell

Moderate Buy

12.76% Upside

Current: 58.240

Low

47.00

Averages

65.67

High

79.00

12.76% Upside

Current: 58.240

Low

47.00

Averages

65.67

High

79.00

Goldman Sachs

Neutral

maintain

$55

2025-07-10

Reason

Goldman Sachs

Price Target

$55

2025-07-10

maintain

Neutral

Reason

Goldman Sachs resumed coverage of Halozyme with a Neutral rating and $55 price target. The firm expects the hares to be range-bound until there is greater regulatory clarity.

Morgan Stanley

Sean Laaman

Overweight -> Equal Weight

downgrade

$73 -> $62

2025-05-14

Reason

Morgan Stanley

Sean Laaman

Price Target

$73 -> $62

2025-05-14

downgrade

Overweight -> Equal Weight

Reason

Leerink

Market Perform -> Underperform

downgrade

$63 -> $47

2025-05-13

Reason

Leerink

Price Target

$63 -> $47

2025-05-13

downgrade

Market Perform -> Underperform

Reason

JP Morgan

Jessica Fye

Hold

Maintains

$55 → $58

2025-04-21

Reason

JP Morgan

Jessica Fye

Price Target

$55 → $58

2025-04-21

Maintains

Hold

Reason

HC Wainwright & Co.

Mitchell Kapoor

Strong Buy

Reiterates

n/a

2025-03-06

Reason

HC Wainwright & Co.

Mitchell Kapoor

Price Target

n/a

2025-03-06

Reiterates

Strong Buy

Reason

Benchmark

Robert Wasserman

Strong Buy

Reiterates

$75

2025-02-20

Reason

Benchmark

Robert Wasserman

Price Target

$75

2025-02-20

Reiterates

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Halozyme Therapeutics Inc (HALO.O) is 10.15, compared to its 5-year average forward P/E of 15.66. For a more detailed relative valuation and DCF analysis to assess Halozyme Therapeutics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

Undervalued

5Y Average PE

15.66

Current PE

10.15

Overvalued PE

20.40

Undervalued PE

10.92

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

14.55

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

18.74

Undervalued EV/EBITDA

10.36

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

8.12

Current PS

0.00

Overvalued PS

11.25

Undervalued PS

5.00

Financials

Annual

Quarterly

FY2025Q1

YoY :

+35.22%

264.86M

Total Revenue

FY2025Q1

YoY :

+48.14%

141.54M

Operating Profit

FY2025Q1

YoY :

+53.72%

118.10M

Net Income after Tax

FY2025Q1

YoY :

+55.00%

0.93

EPS - Diluted

FY2025Q1

YoY :

+21.76%

153.27M

Free Cash Flow

FY2025Q1

YoY :

-1.90%

75.02

Gross Profit Margin - %

FY2025Q1

YoY :

-6.85%

45.72

FCF Margin - %

FY2025Q1

YoY :

+13.69%

44.59

Net Margin - %

FY2025Q1

YoY :

+32.09%

27.25

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

6.6M

USD

3-6

Months

2.1M

USD

6-9

Months

500.1K

USD

0-12

Months

11.5M

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds areSelling! The selling amount has increased 4215.85% over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

495.5K

Volume

6-9

Months

11.5K

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

0.0

Volume

Months

6-9

105.1K

Volume

Months

0-12

0.0

Volume

Months

Congress Trading

Congress areSelling! The selling amount has increased100%over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

16.0K

USD

6-9

Months

0.0

USD

0-12

Months

8.0K

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

6.6M

USD

3-6

Months

2.1M

USD

6-9

Months

500.1K

USD

0-12

Months

11.5M

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

HALO News & Events

Events Timeline

2025-07-23 (ET)

2025-07-23

11:38:34

Halozyme says EU approves new indication for Janssen's Darzalex Faspro

2025-06-30 (ET)

2025-06-30

16:11:36

Halozyme added to Russell 1000 Index

2025-06-20 (ET)

2025-06-20

13:17:10

Halozyme says Argenx received EU approval for Vyvgart with Enhanze for CIDP

News

9.0

07-23Newsfilter

European Commission Approved DARZALEX Faspro® for Adult Patients with Smouldering Multiple Myeloma

9.0

07-23SeekingAlpha

J&J says Darzalex injectable granted EU nod for smouldering multiple myeloma

9.0

07-23PRnewswire

European Commission Approved DARZALEX Faspro® for Adult Patients with Smouldering Multiple Myeloma

People Also Watch

Bright Horizons Family Solutions Inc

Clearwater Analytics Holdings Inc

Jackson Financial Inc

Colliers International Group Inc

Watts Water Technologies Inc

252.780

USD

+0.32%

FAQ

What is Halozyme Therapeutics Inc (HALO) stock price today?

The current price of HALO is 58.24 USD — it has decreased -0.9 % in the last trading day.

HALO

Market Estimates

Valuation Metrics

Forward PE

Forward EV/EBITDA

Forward PS

Financials

Trading Trends

HALO News & Events

Events Timeline

News

People Also Watch

FAQ

What is Halozyme Therapeutics Inc (HALO) stock price today?

What is Halozyme Therapeutics Inc (HALO)'s business?

What is the price predicton of HALO Stock?

What is Halozyme Therapeutics Inc (HALO)'s revenue for the last quarter?

What is Halozyme Therapeutics Inc (HALO)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Halozyme Therapeutics Inc (HALO)'s fundamentals?

How many employees does Halozyme Therapeutics Inc (HALO). have?

What is Halozyme Therapeutics Inc (HALO) market cap?